慢性阻塞性肺疾病诊治指南(2026年修订版)解读 陈亚红教授:谈慢阻肺病共病识别与管理
陈亚红教授解读2026版慢阻肺病指南在共病评估与管理方面的核心更新。
二级教授、主任医师、博士生导师,博士后合作导师 北京大学第三医院呼吸与危重症医学科副主任,北京大学医学部慢性气道疾病中心副主任,科研伦理综合办公室主任 中华医学会呼吸病学分会肺功能学组(筹)副组长 中国健康促进与教育协会数字健康分会主任委员 北京慢性病防治与健康教育研究会呼吸病学专业委员会主任委员 中国康复医学会呼吸康复专业委员会常委 中国抗癌协会肿瘤呼吸病学专业委员会常委 中华结核和呼吸杂志、中华健康管理学杂志等编委、中华医学杂志英文版通讯编委
参考文献:
[1]中华医学会呼吸病学分会,中国医师协会呼吸医师分会. 慢性阻塞性肺疾病诊治指南(2026年修订版)[J]. 中华结核和呼吸杂志,2026,49(00):1146-1191.
[2]国家卫生健康委, 财政部, 国家中医药局, 等. 关于做好2024年基本公共卫生服务工作的通知 [EB/OL]. (2024-09-13) [2026-04-15]. https://www.gov.cn/zhengce/zhengceku/202409/content_6972007.htm
[3]Huang K., Zheng Z., Li W., et al. Sociodemographic correlates with prevalence of comorbidities in patients with chronic obstructive pulmonary disease: a study from a Chinese National Survey. Lancet Reg Health West Pac, 2024, 42: 100937.
[4]Celli B. R., Fabbri L. M., Yohannes A. M., et al. A person-centred clinical approach to the multimorbid patient with COPD. Eur J Intern Med, 2025, 140: 106424.
[5]慢性阻塞性肺疾病多学科诊疗实施与管理专家共识专家组, 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病多学科诊疗实施与管理专家共识(2026版) [J]. 中华医学杂志,2026,106(24):2455-2468.
[6]中国肺癌早诊早治专家组, 中国西部肺癌研究协作中心, 周清华, 等. 中国肺癌低剂量CT筛查指南(2025年版) [J]. 中国肺癌杂志, 2025, 28(12): 887-95.
[7]中国老年医学学会心电与心功能分会, 中华医学会呼吸病学分会慢阻肺病学组, 苏州工业园区东方华夏心血管健康研究院. 心力衰竭合并慢性阻塞性肺疾病的多学科管理专家共识 [J]. 中华内科杂志, 2025, 64(11): 1065-83.
[8]Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2026REPORT) [EB/OL]https://goldcopd.org/2026-gold-report-and-pocket-guide/
[9]McDonagh T. A., Metra M., Adamo M., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J, 2021, 42(36): 3599-726.
[10]Wallstrom O., Stridsman C., Lindberg A., et al. Exacerbation History and Risk of Myocardial Infarction and Pulmonary Embolism in COPD. Chest, 2024, 166(6): 1347-59.
[11]Pirera E, Di Raimondo D, D’Anna L, et al. Risk trajectory of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Eur J Intern Med, 2025, 135:74-82.
[12]Matsunaga K., Yoshida Y., Makita N., et al. Increased Risk of Severe Cardiovascular Events Following Exacerbations of Chronic Obstructive Pulmonary Disease: Results of the EXACOS-CV Study in Japan. Adv Ther, 2024, 41(8): 3362-77.
[13]Hou D., Liu Z., Li X., et al. Impacts of COPD exacerbation history on mortality and severe cardiovascular events among patients with COPD in China: a retrospective cohort study. Respir Res, 2025, 26(1): 252.
[14]Liu Z, Cheang I, Chen Y, et al. Risk of severe cardiovascular events and incidence rate of cardiopulmonary events among patients with COPD in China: a retrospective cohort study. BMJ Open. 2026;16(4):e109712.
[15]Van Gelder I. C., Rienstra M., Bunting K. V., et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2024, 45(36): 3314-414.
[16]Rabe K. F., Martinez F. J., Ferguson G. T., et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med, 2020, 383(1): 35-48.
[17]Papi A., Vestbo J., Fabbri L., et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet, 2018, 391(10125): 1076-84.
[18]Lipson D. A., Barnacle H., Birk R., et al. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med, 2017, 196(4): 438-46.
[19]Singh D., Papi A., Corradi M., et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet, 2016, 388(10048): 963-73.
[20]Bardsley S., Criner G. J., Halpin D. M. G., et al. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respir Med, 2022, 205: 107040.
[21]Singh D, Martinez FJ, Hurst JR, et al. Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS). Am J Respir Crit Care Med, 2025, 211(2):205-214.
[22]van Geffen W. H., Tan D. J., Walters J. A., et al. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2023, 12(12): CD011600.
[23]Richeldi L., Schino P., Bargagli E., et al. TRITRIAL: The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease in an Italian Context of Real Life. Int J Chron Obstruct Pulmon Dis, 2024, 19: 475-87.
[24]Kostikas K., Gogali A., Hillas G. Cardiovascular Disease and Chronic Obstructive Pulmonary Disease: Adding a Third Dimension to the ABE Global Initiative for Chronic Obstructive Lung Disease 2023 Chronic Obstructive Pulmonary Disease Classification. Am J Respir Crit Care Med, 2023, 208(4): 502-4.
[25]中国支气管扩张症临床诊治与研究联盟, 中华医学会呼吸病学分会. 成人支气管扩张症病因学诊断专家共识 [J]. 中华结核和呼吸杂志, 2024, 47(10): 921-32.
[26]Dai Z., Zhong Y., Cui Y., et al. Analysis of clinical characteristics, prognosis and influencing factors in patients with bronchiectasis-chronic obstructive pulmonary disease overlap syndrome: A prospective study for more than five years. J Glob Health, 2024, 14: 04129.
[27]Xing Z., Sun T., Janssens J. P., et al. Airflow obstruction and small airway dysfunction following pulmonary tuberculosis: a cross-sectional survey. Thorax, 2023, 78(3): 274-80.
[28]Wang J., Yu L., Yang Z., et al. Development of chronic obstructive pulmonary disease after a tuberculosis episode in a large, population-based cohort from Eastern China. Int J Epidemiol, 2025, 54(2): dyae174.
[29]Sheng Z. K., Cao W. L., Chu H. L., et al. Airflow Obstruction in Post-tuberculosis Lung Disease: A 5-year Prospective Cohort Study. Biomed Environ Sci, 2026, 39(2): 146-57.
[30]Jin J., Li S., Yu W., et al. Emphysema and bronchiectasis in COPD patients with previous pulmonary tuberculosis: computed tomography features and clinical implications. Int J Chron Obstruct Pulmon Dis, 2018, 13: 375-84.
[31]Jin Jianmin, Yu Wenling, Li Shuling, et al. Factors associated with bronchiectasis in patients with moderate–severe chronic obstructive pulmonary disease. Medicine, 2016, 95(29): e4219.
[32]Seok J., Park S., Yoon E. C., et al. Clinical outcomes of interstitial lung abnormalities: a systematic review and meta-analysis. Sci Rep, 2024, 14(1): 7330.
[33]Zheng J., Guo J., Wang G., et al. Interstitial lung abnormality in COPD is inversely associated with the comorbidity of lung cancer. BMC Pulm Med, 2024, 24(1): 506.
[34]Chen Y. W., Ramsook A. H., Coxson H. O., et al. Prevalence and Risk Factors for Osteoporosis in Individuals With COPD: A Systematic Review and Meta-analysis. Chest, 2019, 156(6): 1092-110.
[35]Sepúlveda-Loyola W., Osadnik C., Phu S., et al. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle, 2020, 11(5): 1164-76.
[36]Alisamir M., Ebrahimi M., Rahim F. Anemia in chronic obstructive pulmonary disease: A systematic review. Respir Investig, 2022, 60(4): 510-21.
[37]Balasubramanian A., Henderson R. J., Putcha N., et al. Haemoglobin as a biomarker for clinical outcomes in chronic obstructive pulmonary disease. ERJ Open Res, 2021, 7(3): 00068-2021.
[38]Nielsen B. B. S., Springborg C. J., Jacobsen P. A., et al. Anemia and polycythemia in patients hospitalised with acute exacerbations of chronic obstructive pulmonary disease: prevalence, patient characteristics, and risk of readmission and mortality. Eur Clin Respir J, 2025, 12(1): 2546672.
[39]Wu S., Yi Q., Luo Y., et al. Hemoglobin and clinical outcomes of in-hospital patients with severe acute exacerbation of chronic obstructive pulmonary disease: a multicenter cohort study. Front Med (Lausanne), 2025, 12: 1674268.
[40]Singh G., Zhang W., Kuo Y. F., et al. Association of Psychological Disorders With 30-Day Readmission Rates in Patients With COPD. Chest, 2016, 149(4): 905-15.
[41]Baird C., Lovell J., Johnson M., et al. The impact of cognitive impairment on self-management in chronic obstructive pulmonary disease: A systematic review. Respir Med, 2017, 129: 130-9.
[42]Chapman K. R., Hurst J. R., Frent S. M., et al. Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. Am J Respir Crit Care Med, 2018, 198(3): 329-39.
[43]国务院办公厅. 关于加快建设分级诊疗体系的若干措施 [EB/OL]. (2026-04-06) [2026-04-15]. https://www.gov.cn/zhengce/content/202604/content_7065030.htm
[44]基本公共卫生服务项目基层慢阻肺病防治管理办公室, 国家慢性呼吸疾病防治办公室, 国家呼吸医学中心, 等. 国家基层慢性阻塞性肺疾病防治及管理实施指南(2025) [J]. 中华结核和呼吸杂志, 2026, 49(1): 11-28.
[45]中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版) [J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205.
[46]Salem A, Ramos M, Hu H, et al. The Health Economic Impact of Optimizing Post-Hospitalization Management For An Exacerbation in Copd Patients in China. Value in Health, 2018, 21.
[47]中华医学会呼吸病学分会, 中华预防医学会呼吸病预防与控制专业委员会, 中国医师协会呼吸医师分会,等. 慢性阻塞性肺疾病急性加重围出院期管理与随访指南(2024年版) [J]. 中华结核和呼吸杂志, 2024, 47(11): 1048-68.
[48]隆寰宇, 张钰, 褚红玲, 等. 基于物联网的慢性阻塞性肺疾病管理 [J]. 上海医学, 2024, 47(10): 598-602.
[49]潘子涵, 李姝润, 陈亚红. 物联网技术在慢性阻塞性肺疾病管理中的研究进展与展望 [J]. 中国全科医学, 2024, 27(35): 4446-54.
*“医学界”力求所发表内容专业、可靠,但不对内容的准确性做出承诺;请相关各方在采用或以此作为决策依据时另行核查。
文章原文
内容来自 医学界,版权归原作者所有。
阅读原文 ↗